Immunotherapeutic approaches in triple-negative breast cancer: Latest research and clinical prospects

Therapeutic Advances in Medical Oncology

Volumn 5, Issue 3, 2013, Pages 169-181

  Stagg, John ^a   Allard, Bertrand ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

basal like; breast cancer; immunotherapy; T cell

Indexed keywords

5' NUCLEOTIDASE; ANTHRACYCLINE; ANTIGEN; ARGININE; CALRETICULIN; CD134 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD30 ANTIGEN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; ESTROGEN RECEPTOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 8; MESOTHELIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OX40 LIGAND; PLATELET DERIVED GROWTH FACTOR; PROGESTERONE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR VACCINE; WNT PROTEIN;

CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MOTILITY; CELL THERAPY; COLORECTAL CANCER; CYTOTOXICITY; DNA DAMAGE; GENE EXPRESSION; GENOMICS; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNITY; X CHROMOSOME;

EID: 84879288623     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012475152     Document Type: Review

References (90)

1. Ademuyiwa F. Bshara W. Attwood K. Morrison C. Edge S. Ambrosone C. et al. (2012) NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PloS ONE 7: e38783.
2. Anders C. Deal A. Miller C. Khorram C. Meng H. Burrows E. et al. (2011) The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 117: 1602–1611.
3. Arnes J. Brunet J. Stefansson I. Bégin L. Wong N. Chappuis P. et al. (2005) Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11: 4003–4011.
4. Bauer K. Brown M. Cress R. Parise C. Caggiano V. (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 109: 1721–1728.
5. Bertucci F. Finetti P. Cervera N. Charafe-Jauffret E. Mamessier E. Adélaïde J. et al. (2006) Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66: 4636–4644.
6. Brahmer J. Tykodi S. Chow L. Hwu W. Topalian S. Hwu P. et al. (2012) Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465.
7. Brossart P. Heinrich K. Stuhler G. Behnke L. Reichardt V. Stevanovic S. et al. (1999) Identification of HLA-A2–restricted T-cell epitopes derived from the MUC 1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309–4317.
8. Cancello G. Maisonneuve P. Rotmensz N. Viale G. Mastropasqua M. Pruneri G. et al. (2010) Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21:1974–1981.
9. Carey L. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492–2502.
10. Cheang M. Voduc D. Bajdik C. Leung S. McKinney S. Chia S. et al. (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368–1376.
11. Chen H. Liakou C. Kamat A. Pettaway C. Ward J. Tang D. et al. (2009) Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci 106: 2729–2734.
12. Chen Y. Ross D. Chiu R. Zhou X. Chen Y. Lee P. et al. (2011) Multiple cancer / testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PloS ONE 6: e17876.
13. Chiba S. Baghdadi M. Akiba H. Yoshiyama H. Kinoshita I. Dosaka-Akita H. et al. (2012) Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 29 July 2012 (Epub ahead of print).
14. Croft M. Duan W. Choi H. Eun S. Madireddi S. Mehta A. (2012) TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol 33: 144–152.
15. Curigliano G. Viale G. Ghioni M. Jungbluth A. Bagnardi V. Spagnoli G. et al. (2011) Cancer–testis antigen expression in triple-negative breast cancer. Ann Oncol 22: 98–103.
16. Curran M. Montalvo W. Yagita H. Allison J. (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B 16 melanoma tumors. Proc Natl Acad Sci 107: 4275–4280.
17. de Nardo D. Brennan D. Rexhepaj E. Ruffell B. Shiao S. Madden S. et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery 1: 54–67.
18. Denkert C. Loibl S. Noske A. Roller M. Müller B. Komor M. et al. (2010) Tumor-Associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105–113.
19. Dent R. Hanna W. Trudeau M. Rawlinson E. Sun P. Narod S. (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115: 423–428.
20. Dent R. Trudeau M. Pritchard K. Hanna W. Kahn H. Sawka C. et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429–4434.
21. Desmedt C. Haibe-Kains B. Wirapati P. Buyse M. Larsimont D. Bontempi G. et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14: 5158–5165.
22. Farmer P. Bonnefoi H. Becette V. Tubiana-Hulin M. Fumoleau P. Larsimont D. et al. (2005) Identification of molecular apocrine breast tumours by microarray analysis. Breast Cancer Res 7: 1–2.
23. Finak G. Bertos N. Pepin F. Sadekova S. Souleimanova M. Zhao H. et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518–527.
24. Foulkes W. Stefansson I. Chappuis P. Bégin L. Goffin J. Wong N. et al. (2003) Germline BRCA 1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95: 1482–1485.
25. Fridman W. Pagès F. Sautès-Fridman C. Galon J. (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298–306.
26. Fulford L. Easton D. Reis-Filho J. Sofronis A. Gillett C. Lakhani S. et al. (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49: 22–34.
27. Gadiot J. Hooijkaas A. Kaiser A. van Tinteren H. van Boven H. Blank C. (2011) Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117: 2192–2201.
28. Gangemi S. Minciullo P. Adamo B. Franchina T. Ricciardi G. Ferraro M. et al. (2012) Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. J Cell Biochem 113: 2122–2125.
29. Gao Q. Wang X. Qiu S. Yamato I. Sho M. Nakajima Y. et al. (2009) Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15: 971–979.
30. Ghiringhelli F. Apetoh L. Tesniere A. Aymeric L. Ma Y. Ortiz C. et al. (2009) Activation of the NLRP 3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat Med 15: 1170–1178.
31. Grigoriadis A. Caballero O. Hoek K. da Silva L. Chen Y. Shin S. et al. (2009) CT-X antigen expression in human breast cancer. Proc Natl Acad Sci 106: 13493–13498.
32. Ha N. Nair V. Reddy D. Mudvari P. Ohshiro K. Ghanta K. et al. (2011) Lactoferrin–endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res 71: 7259–7269.
33. Hammond M. Hayes D. Dowsett M. Allred D. Hagerty K. Badve S. et al. (2010) American Society of Clinical Oncology / College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28: 2784–2795.
34. Hirano F. Kaneko K. Tamura H. Dong H. Wang S. Ichikawa M. et al. (2005) Blockade of B7–H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65: 1089–1096.
35. Ignatiadis M. Singhal S. Desmedt C. Haibe-Kains B. Criscitiello C. Andre F. et al. (2012) Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 30: 1996–2004.
36. Jena B. Dotti G. Cooper L. (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116: 1035–1044.
37. Ju T. Cummings R. (2002) A unique molecular chaperone Cosmc required for activity of the mammalian core 1 B3-galactosyltransferase. Proc Natl Acad Sci 99: 16613–16618.
38. Kähler K. Hauschild A. (2011) Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 9: 277–286.
39. Karn T. Pusztai L. Ruckhäberle E. Liedtke C. Müller V. Schmidt M. et al. (2012) Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer 48: 12–23.
40. Lakshminarayanan V. Thompson P. Wolfert M. Buskas T. Bradley J. Pathangey L. et al. (2012) Immune recognition of tumor-associated mucin MUC 1 is achieved by a fully synthetic aberrantly glycosylated MUC 1 tripartite vaccine. Proc Natl Acad Sci 109: 261–266.
41. Langowski J. Zhang X. Wu L. Mattson J. Chen T. Smith K. et al. (2006) IL-23 promotes tumour incidence and growth. Nature 442: 461–465.
42. Lehmann B. Bauer J. Chen X. Sanders M. Chakravarthy A. Shyr Y. et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750–2767.
43. Liedtke C. Mazouni C. Hess K. André F. Tordai A. Mejia J. et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275–1281.
44. Liu S. Lachapelle J. Leung S. Gao D. Foulkes W. Nielsen T. (2012) CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14: R48.
45. Livasy C. Perou C. Karaca G. Cowan D. Maia D. Jackson S. et al. (2007) Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38: 197–204.
46. Lund M. Trivers K. Porter P. Coates R. Leyland-Jones B. Brawley O. et al. (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113: 357–370.
47. Mahmoud S. Paish E. Powe D. Macmillan R. Grainge M. Lee A. et al. (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29: 1949–1955.
48. Mattarollo S. Loi S. Duret H. Ma Y. Zitvogel L. Smyth M. (2011) Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 71: 4809–4820.
49. Metzger O. de Azambuja E. Quinaux E. Francis P. Buyse M. Crown J. et al. (2010) 11 Lymph node ratio is an independent risk classifier in node positive breast cancer patients: results of the phase III BIG 02–98 trial. Eur J Cancer Suppl 8: 61.
50. Mlecnik B. Tosolini M. Kirilovsky A. Berger A. Bindea G. Meatchi T. et al. (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29: 610–618.
51. Molyneux G. Geyer F. Magnay F. McCarthy A. Kendrick H. Natrajan R. et al. (2010) BRCA 1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7: 403–417.
52. Morgan R. Yang J. Kitano M. Dudley M. Laurencot C. Rosenberg S. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843–851.
53. Narazaki H. Zhu Y. Luo L. Zhu G. Chen L. (2010) CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on Both hematopoietic and nonhematopoietic cells. Blood 115: 1941–1948.
54. Ngiow S. von Scheidt B. Akiba H. Yagita H. Teng M. Smyth M. (2011) Anti-TIM3 antibody promotes T Ccell IFN-γ–mediated antitumor immunity and suppresses established tumors. Cancer Res 71: 3540–3551.
55. Nielsen T. Hsu F. Jensen K. Cheang M. Karaca G. Hu Z. et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367–5374.
56. Palazón A. Teijeira A. Martínez-Forero I. Hervás-Stubbs S. Roncal C. Peñuelas I. et al. (2011) Agonist ati-CD137 m Ab act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 71: 801–811.
57. Perou C. Sørlie T. Eisen M. van de Rijn M. Jeffrey S. Rees C. et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752.
58. Piconese S. Valzasina B. Colombo M. (2008) OX 40 Triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205: 825–839.
59. Porter D. Levine B. Kalos M. Bagg A. June C. (2011) Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725–733.
60. Prat A. Parker J. Karginova O. Fan C. Livasy C. Herschkowitz J. et al. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: 1–18.
61. Quezada S. Peggs K. Curran M. Allison J. (2006) CTLA 4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116: 1935–1945.
62. Rakha E. Ellis I. (2009) Triple-negative/basal-like breast cancer. Pathology 41: 40–47.
63. Rangachari M. Zhu C. Sakuishi K. Xiao S. Karman J. Chen A. et al. (2012) Bat 3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med 18: 1394–1400.
64. Rody A. Karn T. Liedtke C. Pusztai L. Ruckhaeberle E. Hanker L. et al. (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13: R97.
65. Rosenberg S. Yang J. Sherry R. Kammula U. Hughes M. Phan G. et al. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17: 4550–4557.
66. Sakuishi K. Apetoh L. Sullivan J. Blazar B. Kuchroo V. Anderson A. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207: 2187–2194.
67. Schmidt M. Böhm D. von Törne C. Steiner E. Puhl A. Pilch H. et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405–5413.
68. Schmidt M. Hellwig B. Hammad S. Othman A. Lohr M. Chen Z. et al. (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa c as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18: 2695–2703.
69. Shah S. Roth A. Goya R. Oloumi A. Ha G. Zhao Y. et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395–399.
70. Singer K. Gottfried E. Kreutz M. Mackensen A. (2011) Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother 60: 425–431.
71. Stagg J. Beavis P. Divisekera U. Liu M. Möller A. Darcy P. et al. (2012) CD73-deficient mice are resistant to carcinogenesis. Cancer Res 72: 2190–2196.
72. Stagg J. Divisekera U. Duret H. Sparwasser T. Teng M. Darcy P. et al. (2011) CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71: 2892–2900.
73. Stagg J. Divisekera U. McLaughlin N. Sharkey J. Pommey S. Denoyer D. et al. (2010) Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci 107: 1547–1552.
74. Stagg J. Johnstone R. Smyth M. (2007) From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 220: 82–101.
75. Stagg J. Smyth M. (2010) Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29: 5346–5358.
76. Stephens P. Tarpey P. Davies H. Loo P. Greenman C. Wedge D. et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400–404.
77. Tchou J. Wang L. Selven B. Zhang H. Conejo-Garcia J. Borghaei H. et al. (2012) Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 133: 799–804.
78. Teng M. von Scheidt B. Duret H. Towne J. Smyth M. (2011) Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases. Cancer Res 71: 2077–2086.
79. Teschendorff A. Miremadi A. Pinder S. Ellis I. Caldas C. (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8: R157.
80. Theurillat J. Ingold F. Frei C. Zippelius A. Varga Z. Seifert B. et al. (2007) NY-ESO-1 protein expression in primary breast carcinoma and metastases–correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell Infiltration. Int J Cancer 120: 2411–2417.
81. Topalian S. Hodi F. Brahmer J. Gettinger S. Smith D. McDermott D. et al. (2012) Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.
82. Tyagi P. Mirakhur B. (2009) MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 10: 371–374.
83. Valmori D. Dutoit V. Liénard D. Rimoldi D. Pittet M. Champagne P. et al. (2000) Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60: 4499–4506.
84. von Mensdorff-Pouilly S. Verstraeten A. Kenemans P. Snijdewint F. Kok A. Kamp G. et al. (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18: 574–575.
85. Wang L. Fan J. Thompson L. Zhang Y. Shin T. Curiel T. et al. (2011) CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 121: 2371–2382.
86. West N. Milne K. Truong P. Macpherson N. Nelson B. Watson P. (2011) Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13: R126.
87. Wolff A. Hammond M. Schwartz J. Hagerty K. Allred D. Cote R. et al. (2006) American Society of Clinical Oncology / College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118–145.
88. Woo S. Turnis M. Goldberg M. Bankoti J. Selby M. Nirschl C. et al. (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72: 917–927.
89. Yang D. de la Rosa G. Tewary P. Oppenheim J. (2009) Alarmins link neutrophils and dendritic cells. Trends Immunol 30: 531–537.
90. Zhang P. Su D. Liang M. Fu J. (2008) Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 45: 1470–1476.